Cellectis (CLLS)

• Market cap: $471M
• 1 day: -1.88%
• 5 days: 12.2%
• 1 month: 27.45%
• 3 months: 69.31%
• 6 months: 208.55%
• Year to date: 159.12%
• 1 year: 152.15%
• 5 years: -78.79%
• 10 years: -85.77%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 222